Castle Biosciences Inc (CSTL) USD0.001

Castle Biosciences, Inc. is a diagnostics company improving health through tests that guide patient care. The Company’s portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-Melanoma is its risk stratification gene expression profile (GEP) test that predicts the likelihood of positive sentinel lymph node and the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM). DecisionDx-SCC is its GEP test for use in patients with cutaneous squamous cell carcinoma (SCC).